Literature DB >> 12460182

Immunomodulatory action of intravenous immunoglobulin.

W A C Sewell1, S Jolles.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12460182      PMCID： PMC1782817          DOI： 10.1046/j.1365-2567.2002.01545.x

Source DB:  PubMed          Journal:  Immunology        ISSN： 0019-2805            Impact factor:   7.397


× No keyword cloud information.
  65 in total

1.  Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).

Authors:  V Hurez; S V Kaveri; A Mouhoub; G Dietrich; J C Mani; D Klatzmann; M D Kazatchkine
Journal:  Ther Immunol       Date:  1994-10

Review 2.  Pooled human IgG modulates cytokine production in lymphocytes and monocytes.

Authors:  U Andersson; L Björk; U Skansén-Saphir; J Andersson
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

Review 3.  Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy.

Authors:  Y Abe; A Horiuchi; M Miyake; S Kimura
Journal:  Immunol Rev       Date:  1994-06       Impact factor: 12.988

Review 4.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

5.  Tumor necrosis factor and intravenous gammaglobulins in common variable immunodeficiency.

Authors:  C M Farber; A Crusiaux; L Schandené; J P van Vooren; M Goldman; E Dupont; N Tasiaux
Journal:  Clin Immunol Immunopathol       Date:  1994-08

6.  Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo.

Authors:  P Aukrust; S S Frøland; N B Liabakk; F Müller; I Nordøy; C Haug; T Espevik
Journal:  Blood       Date:  1994-10-01       Impact factor: 22.113

7.  Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin).

Authors:  V Ruiz de Souza; M P Carreno; S V Kaveri; A Ledur; H Sadeghi; J M Cavaillon; M D Kazatchkine; N Haeffner-Cavaillon
Journal:  Eur J Immunol       Date:  1995-05       Impact factor: 5.532

8.  In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins.

Authors:  M Toungouz; C H Denys; D De Groote; E Dupont
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

9.  Analysis of natural and disease-associated autoantibody repertoires: anti-endothelial cell IgG autoantibody activity in the serum of healthy individuals and patients with systemic lupus erythematosus.

Authors:  N Ronda; M Haury; A Nobrega; S V Kaveri; A Coutinho; M D Kazatchkine
Journal:  Int Immunol       Date:  1994-11       Impact factor: 4.823

10.  Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin.

Authors:  D Amran; H Renz; G Lack; K Bradley; E W Gelfand
Journal:  Clin Immunol Immunopathol       Date:  1994-11
View more
  34 in total

1.  Immune globulin subcutaneous (human), 20% liquid.

Authors: 
Journal:  P T       Date:  2010-08

Review 2.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

3.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 4.  Anti-inflammatory effect of intravenous immunoglobulin mediated through modulation of complement activation.

Authors:  Hans U Lutz; Peter J Späth
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.

Authors:  L Jeannine Brady
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 6.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 7.  Intravenous immunoglobulin and multiple sclerosis.

Authors:  Anat Achiron; Shmuel Miron
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 8.  Intravenous immunoglobulin and dendritic cells.

Authors:  Namita Misra; Jagadeesh Bayry; Jagadeesh Bayary; Sooryasarathi Dasgupta; Amal Ephrem; Jean-Paul Duong Van Huyen; Sandrine Delignat; Gazzala Hassan; Giuseppina Caligiuri; Antonino Nicoletti; Sebastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 9.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

Review 10.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.